News Release Details
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference
A live webcast of the event can be accessed in the Investors/Presentations & Events section of the Verrica website at http://www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in
FOR MORE INFORMATION, PLEASE CONTACT: Investors:
A. Brian DavisChief Financial Officer 484.453.3300 ext. 103 firstname.lastname@example.org William WindhamSolebury Trout 646.378.2946 email@example.com Media: Zara LockshinSolebury Trout 646.378.2960 firstname.lastname@example.org
Source: Verrica Pharmaceuticals Inc.